You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: January 17, 2025

CLINICAL TRIALS PROFILE FOR CLARITIN


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Claritin

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00550550 ↗ Efficacy and Safety of Grass Sublingual Tablet in Children and Adolescents (P05239 AM3)(COMPLETED) Completed ALK-Abelló A/S Phase 3 2007-11-01 The purpose of the study is to investigate the efficacy and safety of a grass sublingual tablet in children and adolescents with a history of grass-pollen induced rhinoconjunctivitis with or without asthma.
NCT00550550 ↗ Efficacy and Safety of Grass Sublingual Tablet in Children and Adolescents (P05239 AM3)(COMPLETED) Completed Merck Sharp & Dohme Corp. Phase 3 2007-11-01 The purpose of the study is to investigate the efficacy and safety of a grass sublingual tablet in children and adolescents with a history of grass-pollen induced rhinoconjunctivitis with or without asthma.
NCT00562159 ↗ Efficacy and Safety of Grass Sublingual Tablet in Adults (P05238 AM3)(COMPLETED) Completed ALK-Abelló A/S Phase 3 2007-11-01 This purpose of this study is to determine the efficacy and safety of a grass sublingual (under-the-tongue) tablet.
NCT00562159 ↗ Efficacy and Safety of Grass Sublingual Tablet in Adults (P05238 AM3)(COMPLETED) Completed Merck Sharp & Dohme Corp. Phase 3 2007-11-01 This purpose of this study is to determine the efficacy and safety of a grass sublingual (under-the-tongue) tablet.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Claritin

Condition Name

Condition Name for Claritin
Intervention Trials
Healthy 5
Allergic Rhinitis 3
Rhinitis, Allergic, Seasonal 3
Allergy 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Claritin
Intervention Trials
Rhinitis 9
Rhinitis, Allergic 7
Conjunctivitis 3
Rhinitis, Allergic, Seasonal 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Claritin

Trials by Country

Trials by Country for Claritin
Location Trials
United States 36
Canada 4
Hungary 1
Germany 1
Croatia 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Claritin
Location Trials
New Jersey 4
Kentucky 4
Michigan 2
Massachusetts 2
Maryland 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Claritin

Clinical Trial Phase

Clinical Trial Phase for Claritin
Clinical Trial Phase Trials
Phase 4 9
Phase 3 4
Phase 2 2
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Claritin
Clinical Trial Phase Trials
Completed 21
Terminated 2
Not yet recruiting 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Claritin

Sponsor Name

Sponsor Name for Claritin
Sponsor Trials
Merck Sharp & Dohme Corp. 5
Ranbaxy Laboratories Limited 4
Bayer 4
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Claritin
Sponsor Trials
Industry 23
Other 10
NIH 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Claritin: Clinical Trials, Market Analysis, and Projections

Introduction to Claritin

Claritin, with its active ingredient loratadine, is a widely recognized and trusted brand in the allergy medication market. It is known for its non-drowsy formula and effectiveness in treating allergic rhinitis. Here, we will delve into the clinical trials, market analysis, and projections for Claritin.

Clinical Trials and Efficacy

Relief from Allergic Rhinitis Symptoms

Clinical trials have consistently shown that Claritin provides significant relief from allergic rhinitis symptoms. A multicenter, randomized, double-blind study involving 836 subjects demonstrated that Claritin offers consistent symptom relief from day 1 up to 7 days compared to a placebo[4].

Comparison with Other Treatments

Claritin-D, a variant that includes a decongestant, has been shown to provide greater relief of nasal congestion and runny nose compared to placebo and other treatments like Flonase. In one study, Claritin-D 12-hour provided 30% more nasal airflow at hour 1 and maintained better outcomes throughout the study duration[1].

Quality of Life Improvement

Loratadine, the active ingredient in Claritin, has been found to improve patients' quality of life significantly. A study showed that loratadine improved quality of life by 52% more than placebo, based on rhinoconjunctivitis quality of life scores after 2 weeks of treatment[4].

Market Analysis

Global Market Size and Growth

The Claritin market is projected to grow substantially over the forecast period from 2024 to 2031. The market size was valued at USD 0.16 billion in 2023 and is expected to reach USD 0.26 billion by 2031, growing at a CAGR of 5.67%[5].

Market Drivers

Several factors drive the growth of the Claritin market:

  • Product Innovation: Ongoing research and development of novel formulations, such as extended-release variants and combination medicines, appeal to consumers seeking improved convenience and efficacy[5].
  • Alterations in Lifestyle Factors: Urban living and increased exposure to allergens like pollen, dust mites, and pet dander have led to a higher demand for allergy treatments[5].
  • Seasonal Demand: Seasonal allergies, particularly in spring and autumn, result in increased demand for allergy relief medicines like Claritin[5].
  • Promotions and Marketing: Effective marketing techniques enhance brand awareness and stimulate sales[5].

Geographical Segmentation

The Claritin market is segmented geographically into North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa. North America, particularly the United States and Canada, has significant market penetration due to strong brand recognition and high prevalence of allergic conditions. Europe and the Asia-Pacific region also show substantial demand, driven by factors such as rising pollen levels, urbanization, and increased healthcare spending[5].

Market Projections

Growth Trends

The Claritin market is expected to continue its upward trend due to the growing need for non-drowsy antihistamines. The market is poised for significant development, driven by the increasing prevalence of allergic conditions and the expanding healthcare sector[2][5].

Challenges and Restraints

Despite the positive growth projections, the market faces several challenges:

  • Competition from Generic Brands: Generic loratadine products at reduced pricing can constrain the market share of branded Claritin[5].
  • Market Saturation: The presence of numerous established antihistamine medicines might lead to market saturation, complicating Claritin’s efforts to sustain growth[5].
  • Adverse Effects and Consumer Reservations: Possible side effects and consumer reservations about traditional drugs can hinder widespread acceptance[5].
  • Regulatory Challenges: Modifications in legislation or constraints on advertising and marketing can influence the promotion and sale of items[5].

Key Players

The major players in the Claritin market include:

  • Bayer AG
  • Sanofi
  • Pfizer
  • Johnson & Johnson
  • Merck

These companies play a crucial role in the market through their product offerings, marketing strategies, and research and development activities[5].

Loratadine Market Context

The broader loratadine market, which includes Claritin, is also expected to grow. The global loratadine market is projected to register a CAGR of 2% during the forecast period from 2022 to 2027. The COVID-19 pandemic had a significant impact on the healthcare sector, and loratadine has been studied for its potential in treating COVID-19-related conditions, further boosting its market growth[3].

Key Takeaways

  • Clinical Efficacy: Claritin has been proven to provide significant relief from allergic rhinitis symptoms and improve patients' quality of life.
  • Market Growth: The Claritin market is expected to grow at a CAGR of 5.67% from 2024 to 2031.
  • Geographical Segmentation: The market is segmented into key regions, with North America and Europe being significant contributors.
  • Market Drivers: Product innovation, lifestyle factors, seasonal demand, and effective marketing drive the market growth.
  • Challenges: Competition from generic brands, market saturation, and regulatory challenges are key restraints.

FAQs

1. What is the active ingredient in Claritin?

The active ingredient in Claritin is loratadine.

2. How quickly does Claritin-D start to work?

Claritin-D starts to work in as little as 30 minutes[1].

3. What are the key drivers of the Claritin market?

Key drivers include product innovation, alterations in lifestyle factors, seasonal demand, and effective marketing strategies[5].

4. Which regions are significant for the Claritin market?

North America, Europe, and the Asia-Pacific region are significant contributors to the Claritin market[5].

5. What are some of the challenges facing the Claritin market?

Challenges include competition from generic brands, market saturation, adverse effects, and regulatory challenges[5].

Cited Sources

  1. Claritin-D® Efficacy - Claritin.com
  2. Global Claritin Market Size, Trends and Projections - MarketResearchIntellect.com
  3. Loratadine Market - Size, Analysis, Industry Share & Growth - MordorIntelligence.com
  4. Claritin® Efficacy - Claritin.com
  5. Claritin Market Size, Share, Growth, Trends & Forecast - VerifiedMarketResearch.com

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.